To explore this, we investigated whether inhibiting UCHL3 with the small-molecule inhibitor TCID could enhance the sensitivity of GC cells to the CDK4/6 inhibitor palbociclib both in vitro and in vivo. Here, UCHL3 is linked to gastric cancer.